What if chemotherapy wasn’t always necessary for breast cancer patients?
What if a simple DNA test could help doctors decide who truly needs it—and who might safely avoid it?
That’s exactly what a major international study is suggesting.
Researchers led by University College London (UCL) tested more than 4,000 women with early-stage breast cancer across several countries, using a gene test called Prosigna.
Instead of guessing based only on tumour size or spread.
The test looks at the activity of 50 genes linked to cancer growth and predicts how likely the disease is to return.
And the results are striking. Around two-thirds of patients were classed as low risk and did not receive chemotherapy.
Their five-year survival rate was 93.7%, almost identical to the 94.9% seen in those who did undergo chemo.
Treatment Becomes More Personal
So what does that mean in real life? Fewer patients going through fatigue, nausea, hair loss, and the emotional toll of treatment.
That may not even add much benefit.
As Professor Rob Stein from UCL put it, “We’re now using tumour biology rather than just traditional clinical features.
That’s a major shift in how we make decisions.”
One participant, Karen Bonham, described avoiding chemotherapy as an “immense relief,” saying it felt “like Christmas” after the shock of diagnosis.
Still, questions remain. Experts say it’s unclear if the same results apply to younger patients under 40.
So is this the future of cancer care—less blanket chemotherapy, more precision medicine?
It certainly looks like treatment may be getting a lot more personal.
